Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.49 USD | -5.96% | +24.15% | -10.62% |
02/05 | Barrington Ups Price Target on SurModics to $71 From $70, Maintains Outperform Rating | MT |
01/05 | Top Midday Gainers | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- Low profitability weakens the company.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.62% | 463M | C | ||
-3.79% | 184B | C+ | ||
-0.84% | 108B | C | ||
-3.75% | 67.82B | A | ||
+3.45% | 51.05B | B- | ||
+9.04% | 44.67B | B- | ||
+3.40% | 41.78B | B+ | ||
+3.21% | 26.78B | B | ||
+3.66% | 26.59B | A- | ||
+15.23% | 25.86B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SRDX Stock
- Ratings Surmodics, Inc.